Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : JMED - Jones Pharma (specialty pharmaceutical mfr) -- Ignore unavailable to you. Want to Upgrade?

To: DanielleC who wrote (224)	6/28/1999 10:27:00 AM
From: Mikeh	Respond to of 268

Looks like you are right. Very positive remarks ... "BancBoston Robertson Stephens Upgrades JMED to a Strong Buy Rating SAN FRANCISCO, June 28 /PRNewswire/ -- The following is being issued by BancBoston Robertson Stephens, a member of the National Association of Securities Dealers, CRD number 41271: BancBoston Robertson Stephens managing director and senior emerging pharmaceuticals analyst Donald B. Ellis today upgraded Jones Pharma (Nasdaq: JMED - news) to a Strong Buy rating from a Buy. Jones Pharma is a specialty pharmaceuticals company focused on manufacturing, marketing, distributing and selling pharmaceutical products. ''We are raising our rating on Jones Pharma to a Strong Buy from a Buy. We believe the fundamentals of the company are stronger than at any time in the company's history,'' said Ellis. ''We are increasingly confident that Jones Pharma will significantly exceed our second quarter expectations, driven by higher-then-expected revenues and margins. We have set a 12-month price target of $54.'' ''Total prescription growth for April and May has increased 21 percent versus the same period last year, which is almost double our revenue growth forecast of 11.6 percent for second quarter 1999,'' said Ellis. ''We believe the company has entered into a new-product life cycle that will drive revenue and earnings over the next five years, without depending on product acquisitions.''